Mr. Mitchell, Galaxy's CEO, has more than 30 years in the medical diagnostic, device and therapeutic fields, with a focus on delivering products and services benefiting patients, caregivers and providers. Early in his carreer he managed an acute care hospital chemistry lab, where he was recruited to industry and spent the following 14 years at Bayer Diagnostics in product, systems and people management. His experience extends to lifescience and medical device development, engineering and manufacturing, into the veterinary diagnostics and vital signs monitoring market and into the rapid diagnostic lateral flow market. Mr. Mitchell's experience includes managing direct and third-party distribution channel models and includes medical insurance reimbursement and formulary approval processes for federal and private pay systems. He has start-up and small company experience as well. Prior to coming to Galaxy, he led a biotechnology startup through the recession of 2008 to a non-dilutive product licensing funding event supporting continued product research and development.
Dr. Olson, Galaxy’s Founder and CSO, is a Board Certified Ophthalmologist specializing in Vitreoretinal Disease and Surgery. He focuses on the medical and surgical management of retinal diseases such as macular degeneration, diabetic retinopathy, retinal detachment, diabetic eye diseases, retinal vascular occlusion, uveitis, proliferative vitreoretinopathy and more. He received his doctorate from the University of Colorado, Denver Health Sciences Center where he also performed his Residency and Fellowship in Vitreoretinal Diseases and Surgery. Dr. Olson is an Associate Professor at the University Of Colorado School Of Medicine, Ophthalmology specializing on Vitreoretinal Diseases and Surgery. He practices direct patient care at the UCHealth Eye Center at the University of Colorado – Anschutz and at the Denver VA Medical Center. Dr. Olson is the recipient of numerous grants and awards, including the Honor Award from the American Society of Retinal Specialists (2014), Research Incentive Award in Retinal from the PanAmerican Ophthalmological Foundation (2013), Inventor of the Year from the University of Colorado (2012).
Dr. Eaton serves as Chairman and Chief Executive Officer of i2 Pharmaceuticals. He has been active in commercial Bioscience endeavors in Colorado and California and held several executive-level leadership positions. With 35 years in both therapeutics and human diagnostics he is passionate about human health and wellness. His biotech experience also includes participation in successful transitions of private companies becoming public. Dr. Eaton has to date founded five companies in the U.S. focused on pharmaceuticals or diagnostics. Dr. Eaton has notable experience in M&A and post-acquisition integration. He has been involved in the development of FDA approved diagnostic and therapeutic products, as well as, establishing profitable service businesses for the translational medicine life sciences market. Early in his biotech career he served as Vice President of Chemistry at NeXstar Pharmaceuticals where he directed the efforts of more than 50 scientists including the group responsible for the production of the first successful aptamer IND, NX1838 now known as Macugen™ (Eyetech Pharmaceuticals), marketed by Pfizer for age-related macular degeneration. Leading this chemistry effort, he was responsible for the acquisition and operation of chemistry companies in both the US and Europe. Dr. Bruce Eaton is an accomplished innovator with more than 80 patents issued worldwide. Dr. Eaton received his Ph.D. degree in Chemistry from the University of California at Berkeley. In addition to his role as Chairman and CEO of i2 Pharmaceuticals, he currently serves on the board of directors of Velocity Sciences, Galaxy Ophthalmics, Lumos Technology, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) and the Colorado Bioscience Association (CBSA).
Dr. Bhandari, a member of Galaxy's Scientific Advisory Board, is a Board Certified Ophthalmologist at The Eye Institute, a Medical Specialty facility within the Springfield Clinic in Springfield, IL. Dr. Bhandari received his medical degree from New York University School of Medicine, New York, NY. He performed his residency in Ophthalmology at the State University of New York Health Science Center at Brooklyn in Brooklyn, NY and also served as Chief Resident of Ophthalmology while there. He performed his Fellowship in Vitreo Retinal Surgery and Diseases at the University Of Colorado School Of Medicine in Aurora, CO. Dr. Bhandari performs direct patient care and is active in clinical trials and product evaluations for multiple products that address diseases in Ophthalmology.